Covaxin phase 3 data shows 77.8% efficacy: Lancet{br} https://ift.tt/eA8V8J

A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.

from Times of India https://ift.tt/30aDSMa

Comments

Popular posts from this blog

रिश्तों को सुधारने की पहल:इस पर जोर कि कश्मीर ही नहीं, कारोबार पर भी बात हो; भारत को मध्य एशिया तक व्यापार मार्ग दे सकता है पाक (br) https://ift.tt/eA8V8J